Sentiment for Array Biopharma Inc (NASDAQ:ARRY)
Array Biopharma Inc (NASDAQ:ARRY) institutional sentiment increased to 1.88 in Q3 2016. Its up 1.18, from 0.7 in 2016Q2. The ratio improved, as 90 hedge funds opened new and increased holdings, while 48 trimmed and sold equity positions in Array Biopharma Inc. The hedge funds in our partner’s database now possess: 146.57 million shares, up from 122.55 million shares in 2016Q2. Also, the number of hedge funds holding Array Biopharma Inc in their top 10 holdings increased from 3 to 4 for an increase of 1. Sold All: 14 Reduced: 34 Increased: 43 New Position: 47.
Array BioPharma Inc. is a biopharmaceutical firm focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The company has a market cap of $1.90 billion. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib . It currently has negative earnings. The Company’s binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC).
About 499,161 shares traded hands. Array Biopharma Inc (NASDAQ:ARRY) has risen 232.42% since June 27, 2016 and is uptrending. It has outperformed by 218.50% the S&P500.
Analysts await Array Biopharma Inc (NASDAQ:ARRY) to report earnings on February, 7. They expect $-0.17 earnings per share, 0.00% or $0.00 from last year’s $-0.17 per share. After $-0.20 actual earnings per share reported by Array Biopharma Inc for the previous quarter, Wall Street now forecasts -15.00% EPS growth.
According to Zacks Investment Research, “Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company’s proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.”
Redmile Group Llc holds 8.94% of its portfolio in Array Biopharma Inc for 16.66 million shares. Bvf Inc Il owns 6.46 million shares or 8.22% of their US portfolio. Moreover, Sarissa Capital Management Lp has 6.68% invested in the company for 4.30 million shares. The Minnesota-based First Light Asset Management Llc has invested 2.87% in the stock. Kopp Investment Advisors Llc, a Minnesota-based fund reported 329,282 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 1 sale for $15.85 million net activity.
Array Biopharma Inc (NASDAQ:ARRY) Ratings Coverage
Ratings analysis reveals 83% of Array BioPharma’s analysts are positive. Out of 6 Wall Street analysts rating Array BioPharma, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $7 while the high is $10. The stock’s average target of $8.50 is -22.80% below today’s ($11.01) share price. ARRY was included in 7 notes of analysts from June 3, 2016. Jefferies maintained Array Biopharma Inc (NASDAQ:ARRY) rating on Monday, August 29. Jefferies has “Buy” rating and $7 price target. Leerink Swann downgraded Array Biopharma Inc (NASDAQ:ARRY) on Monday, January 30 to “Mkt Perform” rating. The stock has “Overweight” rating given by Piper Jaffray on Monday, September 26. The stock has “Buy” rating given by Suntrust Robinson on Friday, June 3. The firm earned “Outperform” rating on Monday, September 26 by Leerink Swann. On Friday, June 3 the stock rating was initiated by SunTrust with “Buy”. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, August 5.
ARRY Company Profile
Array BioPharma Inc. (Array), incorporated on February 6, 1998, is a biopharmaceutical firm focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Firm has approximately five registration studies that are advancing. The Company’s programs include approximately three cancer drugs, binimetinib (MEK162), encorafenib (LGX818) and selumetinib (partnered with AstraZeneca). Binimetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial; encorafenib is a BRAF inhibitor for cancer, which is in Phase III trial, and selumetinib is a MEK inhibitor for cancer, which is in Phase III trial.
More recent Array Biopharma Inc (NASDAQ:ARRY) news were published by: Fool.com which released: “Why Array BioPharma Inc Stock Surged 108.3% in 2016” on January 09, 2017. Also Benzinga.com published the news titled: “Shorts Seize On Leerink’s Array Biopharma Downgrade” on January 30, 2017. Finance.Yahoo.com‘s news article titled: “Array BioPharma (ARRY) Jumps: Stock Adds 7.5% in Session” with publication date: January 16, 2017 was also an interesting one.
The post Array Biopharma Inc (NASDAQ:ARRY) Sentiment Change Report appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2017/02/01/array-biopharma-inc-nasdaqarry-sentiment-change-report/
No comments:
Post a Comment